United States

2015 Press Releases


2015 | 2014 | 2013 | 2012 | 2011 | 2010
Search News Releases
 
DateTitle  
03/26/15Medtronic Completes Acquisition of Sophono, Inc., Minimally Invasive Bone Conduction Hearing Implant Technology
Acquisition Expands Medtronic's ENT Portfolio with Innovative Hearing Restoration Therapy DUBLIN - March 26, 2015 - Medtronic plc (NYSE: MDT) announced today that it has completed the acquisition of Sophono, Inc., a privately held developer and manufacturer of innovative magnetic hearing implants in Boulder, Colorado. This acquisition enables Medtronic's Ear Nose and Throat (ENT) business to continue its focus on novel therapies and innovative technology solutions and supports Medtronic's thera... 
 Printer Friendly Version
03/25/15Medtronic Highlights New Data in JAMA Surgery Demonstrating Significant Cost Savings and Reduced Patient Hospital Stays Following Minimally Invasive Surgery
Study Shows Patients Who Underwent Laparoscopic Colon Resections Left Hospital Faster, Required Significantly Less Follow Up Care and Fewer Medicines Than Patients Who Underwent Open Surgery DUBLIN - March 25, 2015 - Adding to the clinical benefits and improved patient outcomes associated with minimally-invasive surgery (MIS), Medtronic plc (NYSE: MDT) today highlighted new data demonstrating that patients who underwent minimally invasive colon resection procedures were able to leave the hospit... 
Download PDFPrinter Friendly Version
03/18/15Protégé GPS Self-Expanding Peripheral Stent System Receives FDA Approval for Use in Treating Iliac Artery Stenosis
DUBLIN -- March 18, 2015 -- Medtronic plc (NYSE: MDT) today announced that its Protégé(TM) GPS(TM) self-expanding peripheral stent system has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of stenotic lesions of the common and external iliac arteries.  The news follows the nine-month results of the DURABILITY Iliac study, which were presented at the 2014 VIVA conference in Las Vegas. The results demonstrated the safety and effectiveness of the Protégé GPS ... 
Download PDFPrinter Friendly Version
03/16/15Medtronic Seeks Runners with Medical Technology for 2015 "Global Heroes" Team
APPLICATIONS NOW OPEN:  Selected Runners Receive Entry and Travel to the Medtronic Twin Cities Marathon or Medtronic TC 10 Mile in October DUBLIN - March 16, 2015 - Medtronic announced today that applications are open to runners around the world who benefit from medical technology to represent their country on the tenth Medtronic Global Heroes team.  All runners with eligible medical devices are welcome to apply, regardless of device manufacturer. In nine years, 209 runners representing 28 dif... 
Download PDFPrinter Friendly Version
03/15/15Medtronic CoreValve® System Sustains Superior Survival Benefit Over Open Heart Surgery at Two Years
Investigators Conclude that Results Presented as ACC.15 Late-Breaking Clinical Trial Suggest that Self-Expanding TAVR Should be Considered New Standard of Care DUBLIN and SAN DIEGO - March 15, 2015 - Medtronic plc (NYSE: MDT) today unveiled new, highly anticipated two-year data from the High Risk Study of the CoreValve U.S. Pivotal Trial, which continued to show superior survival benefit at two years for transcatheter aortic valve replacement (TAVR) with the CoreValve® System compared to patient... 
Download PDFPrinter Friendly Version
03/14/15Medtronic to Initiate Clinical Study of Drug-Filled Stent Following Successful Preclinical Results
Novel Platform Enables Controlled, Polymer-Free Drug Elution, Designed to Help Address Next-Generation Technology Challenges  DUBLIN and SAN DIEGO - March 14, 2015 - Advancing its interventional coronary portfolio with breakthrough engineering concepts in device design and technology, Medtronic plc (NYSE: MDT) unveiled the preclinical outcomes of its novel Drug-Filled Stent (DFS) at the 64th Annual Scientific Session of the American College of Cardiology (ACC). The preclinical data showed contro... 
Download PDFPrinter Friendly Version
03/14/15Medtronic CoreValve® Evolut(TM) R System Yields Exceptional Outcomes in First Clinical Study
No Mortality or Stroke at 30-days and Excellent Procedural Results with Next-Generation Recapturable Valve  DUBLIN and SAN DIEGO - March 14, 2015 - Medtronic plc (NYSE: MDT) today announced initial clinical outcomes for its next-generation CoreValve® Evolut(TM) R System. At 30-days, the new recapturable, self-expanding valve showed no incidents of all-cause mortality or stroke in a high and extreme risk patient population.  Data from the Evolut R Study, which enrolled 60 patients from six center... 
Download PDFPrinter Friendly Version
03/12/15Medtronic Initiates Pivotal Studies of Resolute Onyx(TM) Drug-Eluting Stent in United States
Next-Generation Device with CoreWire Technology to be Studied in Wide Spectrum of Patients, Including the Smallest Coronary Arteries  DUBLIN - March 12, 2015 - Medtronic plc (NYSE: MDT) today announced the start of its Resolute Onyx(TM) Clinical Program in the United States, which will evaluate the Resolute Onyx(TM) drug-eluting stent (DES) in patients who have coronary artery disease.  Included in the first phase of the study are patients with small vessels that would require a 2.0 mm stent, wh... 
 Printer Friendly Version
03/03/15Medtronic EVP & CFO Gary Ellis to Speak at Barclays Healthcare Conference
DUBLIN - Mar 3, 2015 - Medtronic plc (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Barclays Global Healthcare Conference in Miami. Gary Ellis, executive vice president and chief financial officer of Medtronic, will make a presentation about Medtronic on Wednesday, March 11, 2015, beginning at 9:30a.m. EDT (8:30a.m. CDT). A live audio webcast of the presentation will be available on March 11, 2015, by clicking on the Investors link on t... 
Download PDFPrinter Friendly Version
02/27/15Medtronic EVP & President Michael J. Coyle to Speak at Cowen Healthcare Conference
DUBLIN - Feb 27, 2015 - Medtronic plc (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Cowen and Company 35th Annual Healthcare Conference in Boston. Michael J. Coyle, executive vice president and president of Medtronic's Cardiac and Vascular Group, will make a presentation about Medtronic on Tuesday, March 3, 2015, beginning at 11:20 a.m. EST (10:20 a.m. CST). A live audio webcast of the presentation will be available on March 3, 2015, b... 
Download PDFPrinter Friendly Version
02/27/15Medtronic Announces Irish High Court Approval of Share Premium Reduction
DUBLIN - February 27, 2015 -Medtronic plc (NYSE:MDT) today announced that the Irish High Court has approved the company's share premium reduction petition, creating the distributable reserves needed to support share repurchases or redemptions and payment of the cash dividend of $0.305 per ordinary share that was previously announced on February 13, 2015. The dividend remains payable on April 17, 2015, to shareholders of record at the close of business on March 30, 2015. The quarterly dividend re... 
Download PDFPrinter Friendly Version
02/24/15FDA Approves the VenaSeal(TM) Closure System for Treatment of Clinically Symptomatic Venous Reflux
VenaSeal Closure System, a Next-Generation Chronic Venous Insufficiency Procedure with Demonstrated Safety and Effectiveness DUBLIN - Feb. 24, 2015 ­­- Medtronic plc today announced U.S. Food and Drug Administration approval for VenaSeal(TM) closure system, a minimally invasive procedure that uses a specially formulated medical adhesive to close lower superficial extremities such as the great saphenous vein in patients with symptomatic venous reflux. Venous reflux disease, also known as chro... 
Download PDFPrinter Friendly Version
02/23/15Medtronic Acquires Advanced Uro-Solutions
NURO Percutaneous Tibial Nerve Stimulation System to Enhance Neuromodulation Product Offerings for Treatment of Bladder Control Issues DUBLIN - Feb. 23, 2015 - Medtronic plc (NYSE: MDT) today announced that it has acquired Advanced Uro-Solutions, a privately-held developer of neurostimulation products for the treatment of bladder control issues based in Elizabethton, Tennessee. Terms of the acquisition agreement, which closed in December 2014, were not disclosed. Advanced Uro-Solutions develop... 
Download PDFPrinter Friendly Version
02/19/15Study Shows Medtronic Deep Brain Stimulation Therapy for Treatment-Resistant Epilepsy Demonstrates Significant and Sustained Seizure Reduction at Five Years
Results Also Show Sustained Safety, Intervals of Seizure Freedom, Improvements in Quality of Life and Reduction in Seizure Severity DUBLIN - February 19, 2015 - Medtronic plc (NYSE: MDT) today announced five-year results from the pivotal SANTE (Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy) trial, the largest clinical study of deep brain stimulation (DBS) therapy for epilepsy in adults with treatment-resistant (refractory) epilepsy characterized by partial-onset seizures. The ... 
Download PDFPrinter Friendly Version
02/19/15Medicare Approves Transitional Pass-Through Payment for Outpatient Use of Medtronic Drug-Coated Balloon
CMS Decision Provides Supplemental Reimbursement to U.S. Hospitals for New Medical Device with Potential to Improve Standard of Care for Peripheral Arterial Disease in Upper Leg DUBLIN - Feb. 19, 2015 - Medtronic plc (NYSE: MDT) announced today that the U.S. Centers for Medicare and Medicaid Services (CMS) has approved a transitional pass-through payment for the company's IN.PACT Admiral drug-coated balloon (DCB) under the Medicare hospital outpatient prospective payment system (OPPS), removing... 
Download PDFPrinter Friendly Version
02/18/15Medtronic Leads Progress Toward an Artificial Pancreas for People with Diabetes
New Data on Future Medtronic Systems and Available MiniMed 640G System Accelerate Progress PARIS - February 18, 2015 - Medtronic plc (NYSE:MDT) is advancing the development and commercialization of artificial pancreas technology with new research demonstrating progress toward future innovations and new systems coming to market. The first clinical study results on Medtronic's Hybrid Closed Loop system will be presented at the upcoming Advanced Technologies and Treatments for Diabetes (ATTD) 8th... 
Download PDFPrinter Friendly Version
02/17/15Medtronic Reports Third Quarter Earnings
Revenue of $4.3 Billion Grew 8% at Constant Currency, 4% as Reported Non-GAAP Diluted EPS of $1.01 Grew 11%; GAAP Diluted EPS of $0.98 Grew 31% U.S. Revenue Grew 8% on Strength of New Products Free Cash Flow of $1.7 Billion; GAAP Cash Flow from Operations of $1.8 Billion Company Completes Acquisition of Covidien at Beginning of Fourth Quarter; Integration Activities Underway DUBLIN - Feb. 17, 2015 - Medtronic plc (NYSE: MDT) today announced financial results for Medtronic, Inc.'s third... 
Download PDFPrinter Friendly Version
02/16/15Medtronic Receives Expanded Indications of the VERTEX® Reconstruction System
Now FDA Cleared for Lateral Mass and Pedicle Screw Fixation in the Posterior Cervical Spine DUBLIN - Feb. 16, 2015 - Medtronic plc (NYSE: MDT), today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for expanded  indications of the VERTEX® Reconstruction System.  The new clearance for the VERTEX® family of products allows for lateral mass and pedicle screws to be used as a form of fixation to treat various pathologies occurring in the posterior cervical ... 
Download PDFPrinter Friendly Version
02/16/15Medtronic Announces CE Mark and European Launch of the Euphora(TM) Semicompliant Coronary Balloon Catheter
Semicompliant Balloon Brings Greater Deliverability to Combat Challenging Coronary Lesions DUBLIN - February 16, 2015 - Medtronic plc (NYSE: MDT) today announced the launch of the Euphora(TM) Semicompliant Balloon Dilatation Catheter in countries that recognize the CE (Conformité Européene) mark. The first patient case with the Euphora Semicompliant Balloon Catheter was recently performed by Richard Edwards, M.D., consultant cardiologist at the Freeman Hospital in Newcastle, United Kingdom. It ... 
Download PDFPrinter Friendly Version
02/13/15The American Heart Association - American Stroke Association and Medtronic Collaborate to Reduce Recurrent Strokes
A Leading Cause of Disability and Death, Many Strokes Have No Known Cause DUBLIN and NASHVILLE, TENN. - Feb. 13, 2015 - The American Heart Association/American Stroke Association (AHA/ASA) and Medtronic plc (NYSE: MDT), today announced a collaboration to reduce the rate of recurrent strokes in the U.S. The two organizations will work together over several years to educate, raise awareness and support effective management of patients who have strokes, one of the most devastating diseases affecti... 
Download PDFPrinter Friendly Version
02/13/15Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2015
DUBLIN - February 13, 2015 - The board of directors of Medtronic plc (NYSE:MDT) today approved a cash dividend of $0.305 per ordinary share, conditioned on receipt of Irish Court administrative approval expected to be received by early March 2015. The dividend is payable on April 17, 2015, to shareholders of record at the close of business on March 30, 2015. The quarterly dividend represents a 9% increase over the prior year. Medtronic, a constituent of the S&P 500 Dividend Aristocrats index, ha... 
Download PDFPrinter Friendly Version
02/12/15FDA Classifies Previous Covidien Field Action for Its Trellis-6(TM) and Trellis-8(TM) Peripheral Infusion Systems As a Class 1 Recall
DUBLIN - February 12, 2015 - Medtronic announced today that a previously communicated global voluntary recall to address an issue with certain lots of its Trellis-6(TM) and Trellis-8(TM) peripheral infusion systems has now been classified as a Class 1 Recall by the U.S. Food and Drug Administration. Customers were previously notified by Covidien of the recall on December 15, 2014.  The company has not received any reports of patient injuries related to this issue. If a patient has received treat... 
Download PDFPrinter Friendly Version
02/12/15Study Analyzes Real-World Use of Medtronic's MiniMed 530G System
Diabetes Technology & Therapeutics Publishes Retrospective Analysis Detailing Impact of Threshold Suspend in Addressing Hypoglycemia DUBLIN - February 12, 2015 - Medtronic plc (NYSE:MDT) today announced results of a retrospective analysis based on real-world data from over 20,000 MiniMed® 530G users, which found that the pump's Threshold Suspend feature reduced hypoglycemia, especially at night, without significantly increasing hyperglycemia. The results, titled "Retrospective Analysis of ... 
Download PDFPrinter Friendly Version
02/11/15Medtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2015
DUBLIN - Feb 11, 2015 - Medtronic plc (NYSE: MDT) announced today it will report financial results for Medtronic, Inc.'s third quarter of its fiscal year 2015 on Tuesday, February 17, 2015. A news release will be issued at approximately 6:15 a.m. Central Standard Time and will be available at http://newsroom.medtronic.com. The earnings news release will include summary financial information for Medtronic Inc.'s third fiscal quarter, which ended January 23, 2015. Medtronic will host a webcast at... 
 Printer Friendly Version
02/11/15Addition of Stent Thrombectomy in Treatment of Acute Ischemic Stroke Patients Reduces Disability in Global Studies
ESCAPE and EXTEND-IA Show Improved Neurological Outcomes with Addition of Stent Thrombectomy DUBLIN - February 11, 2015 - Research presented today at the International Stroke Conference (ISC) in Nashville, Tenn. and published online in The New England Journal of Medicine (NEJM) found that the addition of the Solitaire(TM) Device stent thrombectomy procedure to current pharmaceutical treatment significantly reduced disability in patients suffering stroke. Both the EXtending the Time for Thrombo... 
 Printer Friendly Version
02/11/15Medtronic Insertable Cardiac Monitors Detect Atrial Fibrillation in Stroke Patients in 'Real-World' Study
Findings Reinforce Patient Benefit of Reveal LINQ in Real-World Setting New Data Demonstrate Cost-Effectiveness of Long-Term, Continuous Cardiac Monitoring with Potential to Prevent Recurrent Strokes DUBLIN and NASHVILLE - Feb. 11, 2015 - Medtronic plc (NYSE: MDT), today announced the results of a new "real-world" study of patients who have had a cryptogenic stroke (stroke of unknown cause), in which the Reveal LINQ(TM) Insertable Cardiac Monitor (ICM) detected atrial fibrillation i... 
Download PDFPrinter Friendly Version
02/10/15British Journal of Surgery Publishes Five-Year ClosureFast(TM) Study Results
Results Demonstrate Durability, Effectiveness of Treatment for Chronic Venous Insufficiency DUBLIN - Feb. 10, 2015 - The ClosureFast(TM) endovenous radiofrequency ablation catheter from Medtronic plc (NYSE: MDT) is safe and effective for the treatment of chronic venous insufficiency (CVI) over five years, according to data published in the February 2015 issue of British Journal of Surgery. The five-year results of the ClosureFast Long-Term European Multi-Center Study demonstrate the durabilit... 
Download PDFPrinter Friendly Version
02/05/15Medtronic's Pipeline(TM) Flex Embolization Device Receives FDA Approval
Minimally-Invasive Flow Diversion Device for Unruptured Brain Aneurysms Designed for More Exact and Controlled Placement1 DUBLIN - February 5, 2015 - Medtronic plc (NYSE:MDT), a global leader in medical technology, services and solutions, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its Pipeline(TM) Flex embolization device.  Available through a limited U.S. launch in the coming weeks, Medtronic's latest-generation flow diversion device represents an... 
Download PDFPrinter Friendly Version
02/04/15Medtronic Starts U.S. Launch of IN.PACT Admiral Drug-Coated Balloon for Treatment of Peripheral Arterial Disease in Upper Leg
First Uses of New Medical Device Following FDA Approval Take Place at Hospitals Nationwide DUBLIN - Feb. 4, 2015 - U.S. hospitals this week began using a new medical device from Medtronic plc (NYSE: MDT) called the IN.PACT Admiral drug-coated balloon (DCB) to treat patients with peripheral arterial disease (PAD) in the upper leg, a common cardiovascular condition that causes leg pain and increases the risk of heart attack and stroke. Recently approved by the U.S. Food and Drug Administration, ... 
Download PDFPrinter Friendly Version
02/03/15FDA Grants Pre-Market Approval for Medtronic Melody® Transcatheter Pulmonary Valve
Previously Approved Under Humanitarian Device Exemption (HDE), Melody Valve Shows Safety and Effectiveness in Patients with Congenital Heart Disease DUBLIN and MINNEAPOLIS - February 3, 2015 - Medtronic plc (NYSE: MDT), today announced that its Melody® Transcatheter Pulmonary Valve (TPV) received Pre-Market Approval (PMA) from the United States Food and Drug Administration (FDA) based on strong clinical evidence from three clinical studies demonstrating the valve's effectiveness in delaying ope... 
Download PDFPrinter Friendly Version
02/03/15Medtronic Initiates Trial Evaluating Cryoballoon for Early Persistent AF
Enrollments Underway in France and Germany DUBLIN and MINNEAPOLIS - Feb. 3, 2015 - Medtronic plc (NYSE: MDT) today announced the initiation of the Cryo4 Persistent AF (Cryoballoon Ablation for Early Persistent Atrial Fibrillation) clinical trial. The trial will evaluate the 12-month clinical outcomes of cryoballoon ablation for isolating the pulmonary veins, without additional ablation strategies, using the Medtronic Arctic Front AdvanceTM Cryoballoon system to treat patients with early persist... 
Download PDFPrinter Friendly Version
02/02/15Cardiocom, Medtronic's Patient Monitoring Services Business, Announces Partnerships with Home Health Care Companies
With New LHC Group Service Agreement, Medtronic Now Serves Four of the Five Largest Home Health Care Companies in the United States DUBLIN and MINNEAPOLIS - Feb. 2, 2015 - Medtronic plc (NYSE: MDT) announced today a partnership agreement between its Cardiocom business and LHC Group (NASDAQ: LHCG), a U.S. provider of home health, hospice and comprehensive post-acute healthcare services, to provide integrated clinical telehealth services and medical technology to their patients.  This agreement ... 
 Printer Friendly Version
02/02/15Medtronic Expands Access to the Next Generation CoreValve Evolut R System with New Valve Sizes
CE Mark Approval Received for New 26 mm and 29 mm Valves MINNEAPOLIS - February 2, 2015 - Medtronic plc (NYSE: MDT) today announced CE (Conformité Européene) Mark for the 26 mm and 29 mm sizes of the CoreValve® Evolut(TM) R System, a next generation self-expanding valve that advances performance and deliverability during transcatheter aortic valve implantation (TAVI), while providing the option to recapture (re-sheath the valve back into the catheter) and reposition (move the valve to a new pos... 
Download PDFPrinter Friendly Version
01/29/15Studies Show Benefits of Medtronic SmartShock(TM) Technology and Physician Reports in Protecting Patients from Inappropriate Shocks
New Results from PainFree SST, Shock-Less Studies, Involving Nearly 7,000 Patients, Published in HeartRhythm DUBLIN and MINNEAPOLIS - Jan. 29, 2015 - Medtronic plc (NYSE: MDT) today announced new results from the PainFree SST and Shock-Less clinical studies published in the journal HeartRhythm. The data show that treating patients with Medtronic implantable cardiac devices equipped with SmartShockTM Technology, and that providing clinicians with proactive reports, help physicians deliver lifesa... 
Download PDFPrinter Friendly Version
01/28/15Medtronic Study Finds CoreValve® System Benefits Aortic Stenosis Patients with Prior Coronary Bypass Surgery
Analysis is First to Show Significant Advantages for Transcatheter Aortic Valve in Patients with Prior CABG DUBLIN and SAN DIEGO - January 28, 2015 - Medtronic plc (NYSE: MDT) revealed new one-year clinical data showing that transcatheter aortic valve replacement (TAVR) with the self-expanding CoreValve® System offers advantages in survival and safety compared to surgical aortic valve replacement (SAVR) in high risk aortic stenosis patients who have previously undergone coronary artery bypass ... 
Download PDFPrinter Friendly Version
01/26/15Medtronic Completes Acquisition of Covidien
DUBLIN, Ireland - January 26, 2015 - Medtronic plc (NYSE: MDT), a global leader in medical technology, services and solutions, announced today that it has successfully completed the previously announced acquisition of Covidien plc (NYSE: COV). Under the terms of the acquisition agreement, Medtronic, Inc. and Covidien plc are now combined under Medtronic plc.  Shares of Medtronic plc are expected to begin trading on the New York Stock Exchange (NYSE) under the symbol "MDT" on Tuesday, J... 
Download PDFPrinter Friendly Version
01/26/15Medtronic's Pending Acquisition of Covidien Approved by Irish High Court
Transaction Anticipated to Close on January 26, 2015 MINNEAPOLIS AND DUBLIN, Ireland - January 26, 2015 - Medtronic, Inc. (NYSE: MDT) and Covidien plc (NYSE: COV) today announced that the Irish High Court has sanctioned the Covidien scheme of arrangement pursuant to which Medtronic will acquire Covidien under a new holding company incorporated in Ireland to be named Medtronic plc.  With the Court's approval of the scheme of arrangement, Medtronic and Covidien anticipate that the transaction, wh... 
Download PDFPrinter Friendly Version
01/23/15Medtronic Introduces Enhanced Therapy to Treat Debilitating Symptoms of Serious Stomach Disorder
FDA-Approved System May Provide Long-Term Symptom Relief for Patients Suffering from Gastroparesis MINNEAPOLIS - January 23, 2015 -Medtronic, Inc. (NYSE: MDT) today announced it has received United States Food and Drug Administration (FDA) approval, under a humanitarian device exemption* (HDE),for the Medtronic Enterra® II System. The system is used to treat chronic, intractable (drug-refractory) nausea and vomiting associated with gastroparesis of diabetic or unknown origin when more conserva... 
Download PDFPrinter Friendly Version
01/22/15Covidien Reports First-Quarter 2015 Results
First-quarter net sales up 2% (up 6%, excluding foreign exchange rate movement) First-quarter diluted GAAP earnings per share were $1.12; excluding specified items, adjusted diluted earnings per share were $1.11 DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 22, 2015-- Covidien plc (NYSE: COV) today announced financial results for the first quarter of fiscal 2015. First-quarter net sales of $2.69 billion increased 2% ... 
Download PDFPrinter Friendly Version
01/21/15Medtronic Launches MiniMed 640G System, Breakthrough in Artificial Pancreas Technology, Outside the U.S.
New SmartGuard(TM) Technology Helps People with Diabetes Manage the Challenges of Hypoglycemia MINNEAPOLIS - January 21, 2015 - Medtronic, Inc. (NYSE:MDT) today announced the start of the global launch of the MiniMed(TM) 640G System, the next breakthrough toward an artificial pancreas.  With the introduction of Medtronic's exclusive SmartGuard(TM) technology, MiniMed 640G is designed to help people with diabetes achieve better glucose control through advanced protection from hypoglycemia. The ... 
Download PDFPrinter Friendly Version
01/16/15Medtronic Awards $150,000 Locally in Health Access Grants
Medtronic Philanthropy Grants Support Local Organizations Committed to Expanding Access to Healthcare for the Underserved SANTA ANA, CALIF. - Jan. 16, 2015 - The Lestonnac Free Clinic and CHOC Children's Foundation each received a two-year Health Access Grant from Medtronic Philanthropy in recognition of their continued commitment to improve access to healthcare in Orange County.  Each organization was nominated by a team of Medtronic employees working at the Medtronic Orange County site in San... 
Download PDFPrinter Friendly Version
01/12/15Medtronic Highlights Growth Opportunities at J.P. Morgan Healthcare Conference
SAN FRANCISCO -- Jan. 12, 2015 -- Chairman and CEO Omar Ishrak discussed the future of Medtronic, Inc. (NYSE: MDT) during a presentation to investors at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco today.  The presentation outlined the company's continued focus on creating long-term value in healthcare through its three key strategies of therapy innovation, globalization and economic value. The pending acquisition of Covidien was also highlighted, which is expected to close... 
Download PDFPrinter Friendly Version
01/12/15Medtronic Awards $150,000 Locally in Health Access Grants
Medtronic Philanthropy Grants Support Local Organizations Committed to Expanding Access to Healthcare for the Underserved Goleta, CA - January 12, 2015 - Santa Barbara Neighborhood Clinics, Direct Relief and Jodi House Brain Injury Support Center each received a two-year $50,000 Health Access Grant from Medtronic Philanthropy in recognition of their continued commitment to improve access to healthcare.  Each was nominated by a team of Medtronic Neurosurgery employees working in Goleta, CA. The... 
Download PDFPrinter Friendly Version
01/08/15Medtronic-Sponsored European Clinical Trial to Evaluate Cryoballoon Ablation as First-Line Treatment for Patients with Symptomatic Paroxysmal Atrial Fibrillation
MINNEAPOLIS - Jan. 8, 2015 - Medtronic, Inc., (NYSE:MDT) today announced the initiation of a randomized clinical trial in Europe to assess the benefits of ablation using the Medtronic Arctic Front Advance(TM) cryoballoon as a first-line treatment for atrial fibrillation (AF) patients. While medication is currently considered first-line treatment for AF, clinical research indicates that half of all patients with symptomatic disease do not respond to drug therapy1; earlier ablation may improve tre... 
Download PDFPrinter Friendly Version
01/07/15New Clinical Trial Will Evaluate Antibacterial Envelope in Cardiac Implantable Electronic Device Patients at Risk for Major Infections
Medtronic Announces First Patient Enrollment in the WRAP Infection Clinical Trial MINNEAPOLIS - Jan. 7, 2015 - Medtronic, Inc. (NYSE: MDT)  today announced the first patient enrollment in the WRAP Infection Clinical Trial, which will evaluate the effectiveness of the TYRX(TM) Absorbable Antibacterial Envelope in reducing major infections in patients with cardiac implantable electronic devices (CIEDs) at risk for infection. The global clinical trial also will assess healthcare costs related to t... 
Download PDFPrinter Friendly Version
01/06/15Medtronic Shareholders Approve Proposals Related to Medtronic's Acquisition of Covidien
MINNEAPOLIS - Jan. 6, 2015 - Medtronic, Inc. (NYSE: MDT) announced that all proposals related to Medtronic's acquisition of Covidien were approved by Medtronic's shareholders today.  Based on preliminary vote results, the proposal to adopt the transaction agreement and approve the merger was approved by shareholders owning approximately 95.66 percent of the shares voted at the meeting and approximately 75.18 percent of the outstanding Medtronic shares as of the record date.  The final vote resu... 
Download PDFPrinter Friendly Version
01/06/15Announcement under Irish Takeover Rules -- Results of Covidien plc's Shareholder Meetings
This Announcement is Being Made Solely to Comply with the Requirements of the Irish Takeover Rules. the Information Set out Herein Concerning the Results of Covidien plc's Shareholder Meetings on January 6, 2015 Will Also Be Set out in Covidien plc’s Form 8-K to Be Filed on January 6, 2015 DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 6, 2015-- On January 6, 2015, Covidien plc, a public limited company organized under the laws of Ireland, held a spec... 
 Printer Friendly Version
01/05/15Medtronic CEO Omar Ishrak to Speak at J.P. Morgan Healthcare Conference
MINNEAPOLIS - Jan 5, 2015 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the 33rd annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015, in San Francisco. Omar Ishrak, chairman and chief executive officer of Medtronic, will make a presentation about Medtronic beginning at 9:30 a.m. PST (11:30 a.m. CST). A live audio webcast of the presentation will be available on January 12, 2015, by clicking on the Investo... 
Download PDFPrinter Friendly Version
01/05/15Medtronic Drug-Coated Balloon Receives FDA Approval for Treating Peripheral Artery Disease in Upper Leg
Pivotal Study Shows New Medical Device Provides Exceptional Clinical Outcomes and Reduces Need for Costly Repeat Procedures MINNEAPOLIS -- Jan. 5, 2015 -- Medtronic, Inc. (NYSE: MDT) announced today that the U.S. Food and Drug Administration (FDA) has approved the company's IN.PACT Admiral drug-coated balloon (DCB) for the interventional treatment of peripheral artery disease (PAD) in the upper leg, a serious and common cardiovascular condition that causes pain in the legs and is known to be a... 
Download PDFPrinter Friendly Version

Social Media